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A B S T R A C T
Purpose
Reported survival in patients with myeloproliferative neoplasms (MPNs) shows great variation.
Patients with primary myelofibrosis (PMF) have substantially reduced life expectancy, whereas
patients with polycythemia vera (PV) and essential thrombocythemia (ET) have moderately
reduced survival in most, but not all, studies. We conducted a large population-based study to
establish patterns of survival in more than 9,000 patients with MPNs.
Patients and Methods
We identified 9,384 patients with MPNs (from the Swedish Cancer Register) diagnosed from 1973
to 2008 (divided into four calendar periods) with follow-up to 2009. Relative survival ratios (RSRs)
and excess mortality rate ratios were computed as measures of survival.
Results
Patient survival was considerably lower in all MPN subtypes compared with expected survival in
the general population, reflected in 10-year RSRs of 0.64 (95% CI, 0.62 to 0.67) in patients with
PV, 0.68 (95% CI, 0.64 to 0.71) in those with ET, and 0.21 (95% CI, 0.18 to 0.25) in those with
PMF. Excess mortality was observed in patients with any MPN subtype during all four calendar
periods (P  .001). Survival improved significantly over time (P  .001); however, the improve-
ment was less pronounced after the year 2000 and was confined to patients with PV and ET.
Conclusion
We found patients with any MPN subtype to have significantly reduced life expectancy compared
with the general population. The improvement over time is most likely explained by better overall
clinical management of patients with MPN. The decreased life expectancy even in the most recent
calendar period emphasizes the need for new treatment options for these patients.
J Clin Oncol 30:2995-3001. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Myeloproliferative neoplasms (MPNs) are a group
of clonal hematologic malignancies with great vari-
ation in reported patient life expectancy.1 MPNs,
consisting of polycythemia vera (PV), essential
thrombocythemia (ET), primary myelofibrosis
(PMF), and MPN unclassifiable (MPN-U), are
characterized by a relatively indolent course, which
can be complicated by thromboembolic events, and
transformation to acute myeloid leukemia (AML).
In 2005, new light was shed on the pathophysiology
of MPNs with the discovery of an activating muta-
tion in the Janus kinase 2 domain (JAK2 V617F) of
the erythropoietin receptor, resulting in excess uni-,
bi-, or trilinear myeloproliferation.2-5 Since then,
several newmutations and a familial predisposition
have been described inMPNs.6-8
Althoughprogresshasbeenmade in theunder-
standing of the pathogenesis andmolecular biology
of MPNs, there is still uncertainty regarding re-
ported survival among patients withMPNs. To our
knowledge, there have been only a small number of
population-based studies published on survival in
PV, ET, and PMF, which have either included a
limited number of patients or had a limited
follow-up time.9-12 In these studies as well as clinical
trials, patients with PMF have consistently been re-
ported to have reduced life expectancy.10-14 In the
majority of studies, patients with PV have been ob-
served to havemoderately reduced survival.9,15-18 In
contrast, according to most,10,15,19-22 but not all,23
reports, survivalofpatientswithETisnotaffectedby
the disease.
Toestablishpatternsof survival inpatientswith
MPNs, we conducted a large population-based
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study including more than 9,000 patients with MPNs diagnosed in
Sweden from 1973 to 2008, with follow-up until 2009.
PATIENTS AND METHODS
Registries and Diagnostics
Sweden provides universal medical care for the entire population, cur-
rently approximately 9.5million people. Information regarding patients diag-
nosedwithamalignantdisease inSweden isby lawreported to thepopulation-
basednationwide SwedishCancerRegistry,whichwas established in 1958.24 It
is mandatory for every physician to report each patient with an MPN to the
register; in 1984, the double reporting system (both clinicians and patholo-
gists/cytologists)was introduced forMPNs, increasing the completenessof the
registry.25 Each individual in Sweden receives a unique national registration
number, and every death date is recorded in the Cause of Death Registry.
In Sweden, from the mid 1970s to the late 1990s, the diagnostics of PV,
ET, and PMFwere based on the Polycythemia Vera StudyGroup criteria.26,27
During the study period, certain modifications to the classification of MPNs
weremade.MPN-Uwas introduced into the SwedishCancerRegister in 1993.
Diagnostic criteria were revised in 2001 by theWHO, introducing prefibrotic
PMF as a new entity, separated from ET by bone marrow histology.28 JAK2
status was incorporated into the 2008WHO classification criteria.1 Informa-
tion on the number of allogeneic stem-cell transplantations in patients with
MPNs in Sweden during the study period was obtained from the European
Group for Blood andMarrowTransplantation register, whichwas established
in 1974.
Patient Cohort
We identified all patients diagnosedwith anMPN reported to the Swed-
ish Cancer Register between January 1, 1973, and December 31, 2008. Infor-
mationwas gathered on sex, date of birth, anddate of diagnosis. By linking the
national registration number to the Cause of Death Register, information on
date of death was collected up to December 31, 2009 (end of follow-up).
Patients underwent follow-up from the date of diagnosis until death, emigra-
tion, or end of follow-up, whichever occurred first.
The study was approved by the Stockholm Regional Ethics Review
Board. Informed consent was waived, because we had no contact with
study patients.
Survival Analyses
Relative survival ratios (RSRs) were computed as measures of patient
survival.29,30 Relative survival is defined as the observed survival in the patient
group(whereall deathsare consideredevents)dividedby theexpected survival
of a comparable group from the general population, which is assumed to be
free from the cancer in question. RSR provides a measure of total excess
mortality associated with a diagnosis of MPN, irrespective of whether the
excess mortality was directly or indirectly associated with theMPN. Expected
survival was estimated using the Ederer II method from the Swedish popula-
tion life tables stratified by age, sex, and calendar period.31 One-, 5-, 10-, 15-,
and20-yearRSRswith95%CIswerecalculated forpatientswithMPNsduring
four calendar periods: 1973 to 1982, 1983 to 1992, 1993 to 2000, and 2001 to
2008.The two latter calendarperiodsweremade shorter toobtain amore even
patientdistributionand facilitatedetectionof effectsonsurvival resulting from
introduced changes in classification and treatment. In the most recent calen-
dar period, 1-, 5-, and (because of the limited follow-up time) 8-year RSRs
were calculated. RSRs were calculated separately in patients with different
MPNsubtypes (PV, ET, PMF, andMPN-U) for thewhole cohort and for each
of the four calendar periods. In addition, RSRs were analyzed in patients
diagnosed before versus after 1993, whichwaswhen the categoryMPN-Uwas
introduced.RSRswere calculated forpatients infiveagecategories (50, 50 to
59, 60 to 69, 70 to 79, and 80 years) and separately for men and women.
Poisson regression was used to model excess mortality to estimate the
effects of the factors described while controlling for potential confounding
factors.30 The parameter estimates from this model are interpreted as excess
mortality rate ratios (EMRRs).AnEMRRof 1.5, for example, formen/women
indicates that men experience 50% higher excess mortality than women. All
EMRRs were adjusted for age, sex, and calendar period of diagnosis. All
calculations were performed using STATA version 10.1 (STATA, College
Station, TX).
RESULTS
A total of 9,384 patients with MPNs were identified (PV, n 4,389;
ET, n  2,559; PMF, n  1,048; and MPN-U, n  1,388; Table 1).
There was a higher proportion of women (53%). Median age at
diagnosis was 71 years andwas constant during the last three calendar
periods.The reportednumberofpatients during each calendarperiod
increased over time, beingmore than twice as high in themost recent
calendar period compared with the first (Table 1). Median year of
diagnosis was 1995, and 6,180 patients (66%) died during follow-up.
A total of 71 allogeneic stem-cell transplantations in patients with
MPNs were reported to the European Group for Blood and Marrow
Transplantation register during the study period. Of these, 72%were
carried out during the most recent calendar period (2001 to 2008;
Table 1). The majority of patients receiving transplants (63%)
had PMF.
Patient survival was considerably lower in all MPN subtypes
compared with expected survival in the general population; 10- and
20-year RSRswere 0.64 (95%CI, 0.62 to 0.67) and 0.32 (95%CI, 0.29
to 0.35) for PV, 0.68 (95%CI, 0.64 to 0.71) and 0.44 (95%CI, 0.37 to
0.51) forET, and0.21 (95%CI, 0.18 to 0.25) and0.06 (95%CI, 0.04 to
0.09) for PMF, respectively (Fig 1). Ten- and 15-year RSRs were 0.49
(95% CI, 0.44 to 0.53) and 0.39 (95% CI, 0.32 to 0.47) for patients
classified as MPN-U (Fig 1). Compared with those with PV, patients
with PMF and MPN-U had higher overall excess mortality; EMRRs
were 4.38 (95% CI, 3.90 to 4.91) and 4.57 (95% CI, 3.87 to 5.41) for
PMFandMPN-U, respectively.PatientswithEThadanEMRRof1.83
Table 1. Patient Distribution
Characteristic
Calendar Period
Total
1973 to
1982
1983 to
1992
1993 to
2000
2001 to
2008
Total No. of patients 1,644 2,413 2,292 3,035 9,384
MPN subtype
PV 1,248 1,336 861 944 4,389
ET 157 728 697 977 2,559
PMF 239 349 171 289 1,048
MPN-U — — 563 825 1,388
Age, years
 50 133 221 256 300 910
50-59 233 275 277 458 1,243
60-69 461 605 492 627 2,185
70-79 585 912 788 948 3,233
 80 232 400 479 702 1,813
Median age at
diagnosis, years 69 71 71 71 71
Sex
Male 821 1,135 1,054 1,443 4,453
Female 823 1,278 1,238 1,592 4,931
Male/female ratio 50/50 47/53 46/54 48/52 47/53
No. of SCTs 1 4 15 51 71
Abbreviations: ET, essential thrombocythemia; MPN, myeloproliferative neo-
plasm; MPN-U, MPN unclassified; PMF, primary myelofibrosis; PV, polycythe-
mia vera; SCT, stem-cell transplantation (allogeneic).
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(95% CI, 1.59 to 2.10) using PV as reference (P .001). The inferior
survival of patients with ET compared with those with PV was con-
fined to those diagnosed before 1993 (data not shown). After 1993,
10-year RSRswere 0.72 (95%CI, 0.67 to 0.76) and 0.83 (95%CI, 0.79
to 0.88) for PV and ET, respectively (Fig 2A).
Therewasanexcessmortality inpatientswithanysubtypeduring
all calendar periods. During themost recent calendar period (2001 to
2008), 8-year RSRs were 0.84 (95% CI, 0.77 to 0.90), 0.91 (95% CI,
0.84 to 0.97), 0.48 (95% CI, 0.39 to 0.57), and 0.54 (95% CI, 0.47 to
0.60) in patients with PV, ET, PMF, and MPN-U, respectively
(Fig 2B).
A significant improvement inRSRswas observed over time in an
analysis of the whole MPN cohort (P .001; Fig 3). Compared with
patients diagnosed from 1973 to 1982, EMRRs were 0.60 (95% CI,
0.53 to 0.67) for patients diagnosed from 1983 to 1992, 0.29 (95%CI,
0.25 to 0.34) for patients diagnosed from1993 to 2000, and 0.23 (95%
CI, 0.19 to 0.27) for patients diagnosed from 2001 to 2008 (Table 2).
The improvement between the twomost recent calendar periods was
of borderline significance (P .046). In a stratified analysis of patients
diagnosed before and after 1993, significant improvement in RSRs
over time was seen in patients with PV and ET, whereas no improve-
ment was observed in patients with PMF; 10-year RSRs were 0.21
(95%CI, 0.17 to 0.25) for those with PMFdiagnosed before 1993 and
0.19 (95%CI, 0.12 to 0.27) after 1993.
Older age at MPN diagnosis was associated with poorer survival
(Fig 4A). Improved survival rateswere seen in all age groups, in all but
the most recent calendar period (Fig 4B).
Women had significantly superior survival, with an EMRR
of 0.72 (95% CI, 0.66 to 0.78), compared with men (reference
1.00; Table 2). There was no significant difference in survival of
patients diagnosed at university hospitals compared with
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Fig 2. Cumulative relative survival among patients with myeloproliferative
neoplasms (MPNs) in Sweden, stratified by subtype, diagnosed (A) during the
years 1993 to 2008 and (B) during the most recent calendar period of 2001 to
2008. ET, essential thrombocythemia; MPN-U, MPN unclassifiable; PMF, pri-
mary myelofibrosis; PV, polycythemia vera; RSR, relative survival ratio.
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Fig 1. Cumulative relative survival among patients with myeloproliferative
neoplasms (MPNs) in Sweden, stratified by subtype, during the whole study
period from 1973 to 2008. ET, essential thrombocythemia; MPN-U, MPN
unclassifiable; PMF, primary myelofibrosis; PV, polycythemia vera; RSR, relative
survival ratio.
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nonuniversity hospitals (EMRR, 0.92; 95% CI, 0.84 to 1.01;
Table 2).
DISCUSSION
In this large population-based study including more than 9,000 pa-
tients, we found patients with any MPN subtype to a have inferior
survival compared with the general population during all calendar
periods under study. There was continuous improvement in survival
over time; however, this was less pronounced after the year 2000 as
comparedwith the improvement seen earlier during the studyperiod.
The observed improvement in survival was restricted to patients with
PV and ET, whereas no improvement was seen in patients with PMF.
This underlines the assertion that all MPNs should be considered
diseases that reduce life expectancyandhighlights theneed to improve
treatment strategies for these patients.
In patients with PV, survival was 36% lower than expected in the
general population.Thefinding that PV is associatedwith reduced life
expectancy is supported by most published studies,9,15-18 but it has
not, to our knowledge, been shown in a study this comprehensive
before. Patients with PV in Sweden during the study period were
treated according to international guidelines,32,33 and in 1998, the
Swedish MPN Study Group published the first edition of national
guidelines.34 In theseguidelines,first-line cytoreductive treatmentwas
hydroxyurea and radioactive phosphorus in patients with PV or ET.
For those with PMF, recommended treatment was hydroxyurea or
interferon.34 In a recent study of treatment-related risk factors for
AML in patients withMPN diagnosed in Sweden from 1958 to 2005,
themostcommonstrategies in thispatientcohortwere treatmentwith
hydroxyurea, treatment with radioactive phosphorus, or no cytore-
ductive treatment at all.32 In other studies involving patients with PV,
major causes of death have been thromboembolic events and trans-
formation to AML.16,17 Several factors may have contributed to the
improved survival observed in thosewithPV.Aspirinprophylaxis and
stringent adherence to thehematocrit goals forphlebotomyhavebeen
shown to be beneficial in preventing thromboembolic complica-
tions.35,36 In addition, prognosis after a vascular event has improved
greatly forpatientswithPVaswell as for the general population.37The
leukemogenic effect of alkylating agents and radioactive phosphorus
has been recognized and has led to a decline in the use of these
drugs.18,32,33 However, no cytoreductive therapy so far has been
shown to significantly slow disease progression in PV. Even though a
more widespread blood count screening, introduced during the sec-
ond and third calendar periods,38 most likely led to an earlier estab-
lishment ofMPNdiagnoses (lead timebias29), our findings imply that
better overall clinical management of these patients resulted in the
observed improved outcome.
ET was associated with excess mortality throughout the study
period. This novel finding is in contrast to results from previous
smaller studies with short follow-up time, which reported normal life
expectancy in patientswith ET.10,15,19-21 A few studieswithmore than
10 years of follow-up have reported inferior survival, underlining the
need for long follow-up to detect excess mortality.22,23 As in PV, the
increased risk of thromboembolic events, both at diagnosis and dur-
ing follow-up, in patients with ET is an important contributor to
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Fig 3. Cumulative relative survival among patients with myeloproliferative
neoplasms in Sweden stratified by calendar period of diagnosis. RSR, relative
survival ratio.
Table 2. Excess Mortality Rate Ratios
Characteristic
Excess Mortality
Rate Ratio 95% CI P 
MPN subtype
PV 1.00 (reference)
ET 1.83 1.59 to 2.10  .001
PMF 4.38 3.90 to 4.91  .001
MPN-U 4.57 3.87 to 5.41  .001
Year of diagnosis
1973-1982 1.00 (reference)
1983-1992 0.60 0.53 to 0.67  .001
1993-2000 0.29 0.25 to 0.34  .001
2001-2008 0.23 0.19 to 0.27  .001
Age at diagnosis, years
 50 0.33 0.26 to 0.40  .001
50-59 0.55 0.47 to 0.65  .001
60-69 1.00 (reference)
70-79 1.50 1.34 to 1.67  .001
 80 2.68 2.35 to 3.05  .001
Sex
Male 1.00 (reference)
Female 0.72 0.66 to 0.78  .001
Hospital type
Nonuniversity 1.00 (reference)
University 0.92 0.84 to 1.01 .077
NOTE. Global tests for effect of subtype, calendar period, age, and sex were
all significant (P  .001).
Abbreviations: ET, essential thrombocythemia; MPN, myeloproliferative neo-
plasm; MPN-U, MPN unclassified; PMF, primary myelofibrosis; PV, polycythe-
mia vera.
P values are for test compared with reference; all variables adjusted for
MPN subtype, calendar period of diagnosis, age at diagnosis, and sex.
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mortality in these patients.39,40 As discussed, prophylaxis and treat-
ment of vascular events and the decline in use of leukemogenic drugs
have most likely played an important role in the observed improve-
ment in survival. The reported number of patients in each calendar
period increased over time,most probably reflecting a better coverage
of the registry rather than a true increase in incidence. Theremay also
have been a certain selection in reporting of only the severe ET cases
during first calendar period, resulting in a better survival rate with
increasing registration of the patients with less aggressive disease dur-
ing the later part of the study period. Possible misclassification with
inclusion of patients with early PMF in the ET group may have con-
tributed to the lowRSR in ET before 1993, because patients with early
PMF have inferior survival compared with those with ET.41,42 An
accurate diagnosis differentiating prefibrotic PMF from ET is impor-
tant not only for predicting overall survival but also for assessing the
risk of bleeding complications and transformation to overt myelofi-
brosis and leukemia, both of which are higher in patients with prefi-
brotic PMF. Patients in Sweden, however, were classified according to
the Polycythemia Vera Study Group criteria27 and later the WHO
criteria,1,28 as in previously published studies from the corresponding
calendar periods.10,15,19-23 Even after the introduction of the WHO
classification in 2001, leading gradually to a group of more homoge-
neous patients with ET, this diagnosis was still associated with excess
mortality during the most recent calendar period (2001 to 2008).
Whether true ET is associatedwith normal survival needs to be inves-
tigated in future trials, but until then, ET should be recognized as a
serious disease affecting life expectancy.
As previously reported,10-14 PMF was the subtype associated
with the lowest relative survival; in addition, we found no improve-
ment in survival over time. Patients with PMF have a higher rate of
transformation to AML and myelodysplastic syndrome32,42 com-
pared with patients with other subtypes; additionally, these patients
experience a high risk of thromboembolic and hemorrhagic events,
contributing largely to the excessmortality.43 Only a small number of
patients underwent allogeneic stem-cell transplantation, which
is the only known cure for PMF but is associated with substantial
transplantation-related mortality.44 Several novel agents have
been investigated in PMF, such as thalidomide, lenalidomide, and
JAK2 inhibitors, but only a few patients during this study period
were included in clinical trials of these drugs. Apart from smaller
reports on interferon possibly reducing bone marrow fibrosis,45 no
treatment has been shown to modify disease progression.8,46 There
are, however, promising data on symptom relief with JAK2 inhibi-
tors,47 and ina recentpreliminary report, a survival benefitwas seen in
patients with PMF treated with JAK2 inhibitors when compared
with placebo.48
MPN-U is a heterogeneous group including both patients in
early as well as late disease stages who do notmeet the criteria for PV,
ET, or PMF.1 The excessmortality seen in patients withMPN-Umay
be explained by a predominance of patients in this group having late
stage disease, including secondary myelofibrosis, which in turn is
associated with highmortality.1
Age was a strong predictor of prognosis; higher age at diagnosis
predicted poorer relative survival during all calendar periods. Similar
resultswere reported in theECLAP(EuropeanCollaborationonLow-
doseAspirin in PolycythemiaVera) trial.49 Possibly, older patients are
affected by amore aggressive disease and/or higher rate of treatment-
related complications. Some authors have reported less optimal strin-
gency to treatment guidelines and less restrictive use of leukemogenic
drugs in older patients because of the expected shorter survival.32,49,50
This needs tobe addressed in the clinical setting tooptimize treatment
for elderly patients.
Female patients with MPNs had better outcome than male pa-
tients. Superior survival in female patients has been shown in many
other studies of hematologic malignancies,15,51,52 but the underlying
causes of the better outcome in women are currently unknown. It is
possible that this could reflect variations in biology, treatment, and/or
lifestyle factors.
The strengths of our study include a register-based cohort design
including a large number of patients over a period of 36 years, ensur-
ing a population-based setting and generalizationof our findings. The
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Fig 4. (A) Cumulative relative survival among patients with myeloproliferative
neoplasms (MPNs) in Sweden stratified by age at diagnosis and (B) estimates of
5-year cumulative relative survival ratios (RSRs) among patients with MPNs
stratified by age and calendar period of diagnosis.
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Swedish Cancer Register consists of prospectively collected data and
has a high diagnostic validity for hematologic malignancies.24
A limitation of this study is the lack of detailedmedical informa-
tion such as clinical and laboratory data in the Swedish Cancer Regis-
ter; we were therefore not able to confirm individual diagnoses. In
addition, as discussed, there were changes to the classification system
during the study period, which may have influenced the comparison
of survival and risk of complications in different MPN subtypes
over time.
In summary, in this large population-based study, we found all
MPNsubtypes tohave significantly reduced life expectancy compared
with the general population, even in themost recent calendar period.
Survival improved over time in patients with PV andET and in all age
groups.Therewasno improvement in survival in thosewithPMF,and
only marginal improvement was observed between the two most
recent calendar periods in the whole MPN cohort. Apart from better
prophylaxis andmanagement of disease complications, in contrast to
chronic myelogenous leukemia, no disease-specific therapy has been
shown to significantly improve survival in MPNs.50 Ongoing and
future studies of the molecular background of MPNs and the under-
lying causes of the observed excess mortality are needed to enhance
our understanding of these diseases. The reduced life expectancy seen
in this study in allMPN subtypes underlines the need to optimize our
current treatment strategies and highlights the need for new disease-
modifying therapies to change the outlook for patients withMPNs.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
The author(s) indicated no potential conflicts of interest.
AUTHOR CONTRIBUTIONS
Conception and design: All authors
Financial support:Magnus Bjo¨rkholm
Administrative support:Magnus Bjo¨rkholm
Collection and assembly of data:Malin Hultcrantz, Sigurdur Yngvi
Kristinsson, Therese M.-L. Andersson, Magnus Bjo¨rkholm
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
1. Swerdlow SH, Campo E, Harris NL, et al (eds):
WHO Classification of Tumours of Haematopoietic
and Lymphoid Tissues. Lyon, France, IARC Press,
2008
2. Kralovics R, Passamonti F, Buser AS, et al: A
gain-of-function mutation of JAK2 in myeloprolifera-
tive disorders. N Engl J Med 352:1779-1790, 2005
3. Levine RL, Wadleigh M, Cools J, et al: Acti-
vating mutation in the tyrosine kinase JAK2 in poly-
cythemia vera, essential thrombocythemia, and
myeloid metaplasia with myelofibrosis. Cancer Cell
7:387-397, 2005
4. James C, Ugo V, Le Coue´dic JP, et al: A
unique clonal JAK2 mutation leading to constitutive
signalling causes polycythaemia vera. Nature 434:
1144-1148, 2005
5. Baxter EJ, Scott LM, Campbell PJ, et al:
Acquired mutation of the tyrosine kinase JAK2 in
human myeloproliferative disorders. Lancet 365:
1054-1061, 2005
6. Landgren O, Goldin LR, Kristinsson SY, et al:
Increased risks of polycythemia vera, essential
thrombocythemia, and myelofibrosis among 24,577
first-degree relatives of 11,039 patients with my-
eloproliferative neoplasms in Sweden. Blood 112:
2199-2204, 2008
7. Jones AV, Chase A, Silver RT, et al: JAK2
haplotype is a major risk factor for the development
of myeloproliferative neoplasms. Nat Genet 41:446-
449, 2009
8. Tefferi A, Vainchenker W: Myeloproliferative
neoplasms: Molecular pathophysiology, essential
clinical understanding, and treatment strategies.
J Clin Oncol 29:573-582, 2011
9. Ania BJ, Suman VJ, Sobell JL, et al: Trends in
the incidence of polycythemia vera among Olmsted
County, Minnesota residents, 1935-1989. Am J He-
matol 47:89-93, 1994
10. Mesa RA, Silverstein MN, Jacobsen SJ, et al:
Population-based incidence and survival figures in
essential thrombocythemia and agnogenic myeloid
metaplasia: An Olmsted County study, 1976-1995.
Am J Hematol 61:10-15, 1999
11. Maynadie´ M, Girodon F, Manivet-Janoray I, et
al: Twenty-five years of epidemiological recording
on myeloid malignancies: Data from the specialized
registry of hematologic malignancies of Cote d’Or
(Burgundy, France). Haematologica 96:55-61, 2011
12. Rollison DE, Howlader N, Smith MT, et al:
Epidemiology of myelodysplastic syndromes and
chronic myeloproliferative disorders in the United
States, 2001-2004, using data from the NAACCR
and SEER programs. Blood 112:45-52, 2008
13. Cervantes F, Dupriez B, Pereira A, et al: New
prognostic scoring system for primary myelofibrosis
based on a study of the International Working Group
for Myelofibrosis Research and Treatment. Blood
113:2895-2901, 2009
14. Passamonti F, Cervantes F, Vannucchi AM, et
al: A dynamic prognostic model to predict survival in
primary myelofibrosis: A study by the IWG-MRT
(International Working Group for Myeloproliferative
Neoplasms Research and Treatment). Blood 115:
1703-1708, 2010
15. Passamonti F, Rumi E, Pungolino E, et al: Life
expectancy and prognostic factors for survival in
patients with polycythemia vera and essential
thrombocythemia. Am J Med 117:755-761, 2004
16. Marchioli R, Finazzi G, Landolfi R, et al: Vas-
cular and neoplastic risk in a large cohort of patients
with polycythemia vera. J Clin Oncol 23:2224-2232,
2005
17. Gruppo Italiano Studio Policitemia: Polycythe-
mia vera: The natural history of 1213 patients fol-
lowed for 20 years. Ann Intern Med 123:656-664,
1995
18. Kiladjian JJ, Chevret S, Dosquet C, et al:
Treatment of polycythemia vera with hydroxyurea
and pipobroman: Final results of a randomized trial
initiated in 1980. J Clin Oncol 29:3907-3913, 2011
19. Palandri F, Catani L, Testoni N, et al: Long-
term follow-up of 386 consecutive patients with
essential thrombocythemia: Safety of cytoreductive
therapy. Am J Hematol 84:215-220, 2009
20. Rozman C, Giralt M, Feliu E, et al: Life expec-
tancy of patients with chronic nonleukemic my-
eloproliferative disorders. Cancer 67:2658-2663,
1991
21. Passamonti F, Rumi E, Arcaini L, et al:
Prognostic factors for thrombosis, myelofibrosis,
and leukemia in essential thrombocythemia: A
study of 605 patients. Haematologica 93:1645-
1651, 2008
22. Bazzan M, Tamponi G, Schinco P, et al:
Thrombosis-free survival and life expectancy in 187
consecutive patients with essential thrombocythe-
mia. Ann Hematol 78:539-543, 1999
23. Wolanskyj AP, Schwager SM, McClure RF, et
al: Essential thrombocythemia beyond the first de-
cade: Life expectancy, long-term complication rates,
and prognostic factors. Mayo Clin Proc 81:159-166,
2006
24. Turesson I, Linet MS, Bjo¨rkholm M, et al:
Ascertainment and diagnostic accuracy for hemato-
poietic lymphoproliferative malignancies in Sweden
1964-2003. Int J Cancer 121:2260-2266, 2007
25. Official Statistics of Sweden Stockholm, Na-
tional Board of Health and Welfare, Centre for
Epidemiology: Cancer Incidence in Sweden 2010.
http://www.socialstyrelsen.se/Lists/Artikelkatalog/
Attachments/18530/2011-12-15.pdf
26. Berlin NI: Diagnosis and classification of the
polycythemias. Semin Hematol 12:339-351, 1975
27. Murphy S, Peterson P, Iland H, et al: Experi-
ence of the Polycythemia Vera Study Group with
essential thrombocythemia: A final report on diag-
nostic criteria, survival, and leukemic transition by
treatment. Semin Hematol 34:29-39, 1997
28. Jaffe ES, Harris NL, Stein H, et al (eds): World
Health Organization Classification of Tumours: Pa-
thology and Genetics of Tumours of Haematopoietic
and Lymphoid Tissues. Lyon, France, IARC Press,
2001
29. Dickman PW, Adami HO: Interpreting trends
in cancer patient survival. J Intern Med 260:103-117,
2006
30. Dickman PW, Sloggett A, Hills M, et al: Re-
gression models for relative survival. Stat Med 23:
51-64, 2004
31. Ederer F: Instructions to IBM 650 program-
mers in processing survival computations [method-
ological note No. 10]. Bethesda, MD, End Results
Evaluation Section, 1959
Hultcrantz et al
3000 © 2012 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
32. Bjo¨rkholm M, Derolf AR, Hultcrantz M, et al:
Treatment-related risk factors for transformation to
acute myeloid leukemia and myelodysplastic syn-
dromes in myeloproliferative neoplasms. J Clin On-
col, 2011
33. Barbui T, Barosi G, Birgegard G, et al:
Philadelphia-negative classical myeloproliferative
neoplasms: Critical concepts and management rec-
ommendations from European LeukemiaNet. J Clin
Oncol 29:2410-2415, 2011
34. Birgegård G, Bjo¨rkholm M, Kutti J, et al:
Polycythemia vera, essential trombocythemia and
myelofibrosis: Diagnosis, treatment and follow-up—
Recommendations from a national working group
1998 [in Swedish]. Stockholm, Sweden, Swedish
Orphan AB, 1998
35. Landolfi R, Marchioli R, Kutti J, et al: Efficacy
and safety of low-dose aspirin in polycythemia vera.
N Engl J Med 350:114-124, 2004
36. Pearson TC, Wetherley-Mein G: Vascular occlu-
sive episodes and venous haematocrit in primary pro-
liferative polycythaemia. Lancet 2:1219-1222, 1978
37. Stenestrand U, Lindba¨ck J, Wallentin L: Long-
term outcome of primary percutaneous coronary
intervention vs prehospital and in-hospital thrombol-
ysis for patients with ST-elevation myocardial infarc-
tion. JAMA 296:1749-1756, 2006
38. Merk K, Mattsson B, Mattsson A, et al: The
incidence of cancer among blood donors. Int J
Epidemiol 19:505-509, 1990
39. Carobbio A, Thiele J, Passamonti F, et al: Risk
factors for arterial and venous thrombosis in WHO-
defined essential thrombocythemia: An international
study of 891 patients. Blood 117:5857-5859, 2011
40. Harrison CN, Campbell PJ, Buck G, et al:
Hydroxyurea compared with anagrelide in high-risk
essential thrombocythemia. N Engl J Med 353:33-
45, 2005
41. Thiele J, Kvasnicka HM: Chronic myeloprolifer-
ative disorders with thrombocythemia: A comparative
study of two classification systems (PVSG, WHO) on
839 patients. Ann Hematol 82:148-152, 2003
42. Barbui T, Thiele J, Passamonti F, et al: Survival
and disease progression in essential thrombocythe-
mia are significantly influenced by accurate morpho-
logic diagnosis: An international study. J Clin Oncol
29:3179-3184, 2011
43. Barbui T, Carobbio A, Cervantes F, et al:
Thrombosis in primary myelofibrosis: Incidence and
risk factors. Blood 115:778-782, 2010
44. Abelsson J, Merup M, Birgegård G, et al: The
outcome of allo-HSCT for 92 patients with myelofi-
brosis in the Nordic countries. Bone Marrow Trans-
plant 47:380-386, 2012
45. Silver RT, Vandris K, Goldman JJ: Recombi-
nant interferon-alpha may retard progression of early
primary myelofibrosis: A preliminary report. Blood
117:6669-6672, 2011
46. Merup M, Kutti J, Birgergård G, et al: Negligi-
ble clinical effects of thalidomide in patients with
myelofibrosis with myeloid metaplasia. Med Oncol
19:79-86, 2002
47. Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK
inhibition with ruxolitinib versus best available ther-
apy for myelofibrosis. N Engl J Med 366:787-798,
2012
48. Verstovsek S, Mesa RA, Gotlib J, et al: A
double-blind, placebo-controlled trial of ruxolitinib for
myelofibrosis. N Engl J Med 366:799-807, 2012
49. Finazzi G, Caruso V, Marchioli R, et al: Acute
leukemia in polycythemia vera: An analysis of 1638
patients enrolled in a prospective observational
study. Blood 105:2664-2670, 2005
50. Bjo¨rkholm M, Ohm L, Eloranta S, et al: Suc-
cess story of targeted therapy in chronic myeloid
leukemia: A population-based study of patients di-
agnosed in Sweden from 1973 to 2008. J Clin Oncol
29:2514-2520, 2011
51. Derolf AR, Kristinsson SY, Andersson TM, et
al: Improved patient survival for acute myeloid leu-
kemia: A population-based study of 9729 patients
diagnosed in Sweden between 1973 and 2005.
Blood 113:3666-3672, 2009
52. Kristinsson SY, Dickman PW, Wilson WH, et
al: Improved survival in chronic lymphocytic leu-
kemia in the past decade: A population-based
study including 11,179 patients diagnosed be-
tween 1973-2003 in Sweden. Haematologica 94:
1259-1265, 2009
■ ■ ■
Survival Patterns in MPN
www.jco.org © 2012 by American Society of Clinical Oncology 3001
